Simvastatin Tablet, Film Coated
Product Images NDC 71335-1905

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Simvastatin (NDC 71335-1905). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Footnote For Table 3 (Footnote For Table 3)

Footnote For Table 3 (Footnote For Table 3)
This text provides information on the results of chemical assay tests, with specific mention of some inhibitors that could affect the results. It also explains the meaning of Simvastatin acid, and warns that the effects of different amounts of grapefruit juice in simvastatin pharmacokinetics have not been studied. The text details the dosage and frequency of grapefruit juice and simvastatin administration during an experiment in both double-strength and single-strength scenarios.*
FDA Label Image

Label (Lbl713351905)

Label (Lbl713351905)
The text contains information about a medication named Simvastatin 10. The medication appears to be supplied in a package of 30 tablets, each weighing 10mg. It comes in an orange oval shape, with the imprint code 'B301;10' on it. The medication is a generic version of Zocor 10mg tab, which should be kept at room temperature between 20°C-25°C (68°-77°F), and away from children. The product appears to be manufactured by a company called Pura Cap Caribe, and the product code is NDC 7133519051 03392301523487.*
FDA Label Image

Figure 9 (Simvastatin 10)

Figure 9 (Simvastatin 10)
FDA Label Image

Table2 (Simvastatin 2)

Table2 (Simvastatin 2)
The table lists adverse reactions reported for patients treated with Simvastatin compared to Placebo. The reactions reported in the following categories: Body as a Whole, Cardiovascular System Disorders, Digestive System Disorders, Endocrine Disorders, Musculoskeletal Disorders, Nervous System/Psychiatric Disorders, Respiratory System Disorders, Skin/Skin Appendage Disorders, and Urogenital System Disorders. The percentage of patients experiencing each reaction is provided for each treatment group.*
FDA Label Image

Structure (Simvastatin 3)

Structure (Simvastatin 3)
FDA Label Image

Table 3 (Simvastatin 4)

Table 3 (Simvastatin 4)
FDA Label Image

Table 4 (Simvastatin 5)

Table 4 (Simvastatin 5)
FDA Label Image

Figure 5 (Simvastatin 6)

Figure 5 (Simvastatin 6)
FDA Label Image

Figure 6 (Simvastatin 7)

Figure 6 (Simvastatin 7)
FDA Label Image

Figure 7 (Simvastatin 8)

Figure 7 (Simvastatin 8)
FDA Label Image

Figure 8 (Simvastatin 9)

Figure 8 (Simvastatin 9)
FDA Label Image

Table 1 (Table1)

Table 1 (Table1)
This is a table outlining drug interactions associated with increased risk of myopathy/rhabdomyolysis for prescribing recommendations. The table includes a list of interacting agents, such as strong CYP3A4 inhibitors, HIV protease inhibitors, and verapamil. The table also advises caution and limitations when prescribing certain medications with simvastatin and recommends avoiding grapefruit juice.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.